Cargando…

CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)

Anti-CTLA-4-antibodies can induce long-lasting tumor remissions. However, only a few patients respond, necessitating the development of predictive companion biomarkers. Increasing evidence suggests a major role of epigenetics, including DNA methylation, in immunology and resistance to immune checkpo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fietz, Simon, Zarbl, Romina, Niebel, Dennis, Posch, Christian, Brossart, Peter, Gielen, Gerrit H., Strieth, Sebastian, Pietsch, Torsten, Kristiansen, Glen, Bootz, Friedrich, Landsberg, Jennifer, Dietrich, Dimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139923/ https://www.ncbi.nlm.nih.gov/pubmed/33196890 http://dx.doi.org/10.1007/s00262-020-02777-4

Ejemplares similares

CTLA4 DNA methylation is associated with CTLA-4 expression and predicts response to immunotherapy in head and neck squamous cell carcinoma
por: Hoffmann, Friederike, et al.
Publicado: (2023)

Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma
por: Fröhlich, Anne, et al.
Publicado: (2020)

Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma
por: Hoffmann, Friederike, et al.
Publicado: (2020)

Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma
por: Fröhlich, Anne, et al.
Publicado: (2020)

CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
por: Camacho, Luis H
Publicado: (2015)

Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab
por: Karimi, Amirali, et al.
Publicado: (2021)

Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma
por: Holderried, Tobias A. W., et al.
Publicado: (2019)

Nectin-4 is widely expressed in head and neck squamous cell carcinoma
por: Sanders, Christine, et al.
Publicado: (2022)

CTLA-4 antibody ipilimumab negatively affects CD4(+) T-cell responses in vitro
por: Rosskopf, Sandra, et al.
Publicado: (2019)

Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies
por: He, Mengnan, et al.
Publicado: (2017)

CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma
por: Klümper, Niklas, et al.
Publicado: (2021)

A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma
por: Maki, Robert G., et al.
Publicado: (2013)

DNA methylation regulates TIGIT expression within the melanoma microenvironment, is prognostic for overall survival, and predicts progression-free survival in patients treated with anti-PD-1 immunotherapy
por: Niebel, Dennis, et al.
Publicado: (2022)

CTLA-4 Insufficiency due to a Novel CTLA-4 Deletion, Identified through Copy Number Variation Analysis
por: Olfe, Lisa, et al.
Publicado: (2022)

Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels
por: Leung, Anna M., et al.
Publicado: (2014)

Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis
por: Venditti, Olga, et al.
Publicado: (2015)

2081: Phenotypic characterization of the CD4+ T-cell response during anti-CTLA4 therapy with ipilimumab in melanoma patients
por: Sherani, Farha, et al.
Publicado: (2018)

Lack of association between sCTLA-4 levels in human plasma and common CTLA-4 polymorphisms
por: Berry, Andrew, et al.
Publicado: (2008)

ICOS DNA methylation regulates melanoma cell-intrinsic ICOS expression, is associated with melanoma differentiation, prognosis, and predicts response to immune checkpoint blockade
por: Ralser, Damian J., et al.
Publicado: (2023)

Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management
por: Tarhini, Ahmad
Publicado: (2013)

An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients
por: Colston, Elizabeth, et al.
Publicado: (2018)

CTLA-4: From conflict to clinic
por: Bashyam, Hema
Publicado: (2007)

The role of CTLA-4 in immune regulation
por: Verhagen, Johan, et al.
Publicado: (2008)

Activated CTLA‐4‐independent immunosuppression of Treg cells disturbs CTLA‐4 blockade‐mediated antitumor immunity
por: Watanabe, Tomofumi, et al.
Publicado: (2023)

Functional Relevance of CTLA4 Variants: an Upgraded Approach to Assess CTLA4-Dependent Transendocytosis by Flow Cytometry
por: Rojas-Restrepo, Jessica, et al.
Publicado: (2023)

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
por: Peggs, Karl S., et al.
Publicado: (2009)

Correction to: Functional Relevance of CTLA4 Variants: an Upgraded Approach to Assess CTLA4‑Dependent Transendocytosis by Flow Cytometry
por: Rojas‑Restrepo, Jessica, et al.
Publicado: (2023)

PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas
por: Franzen, Alina, et al.
Publicado: (2017)

Fibroblast growth factor (FGF), FGF receptor (FGFR), and cyclin D1 (CCND1) DNA methylation in head and neck squamous cell carcinomas is associated with transcriptional activity, gene amplification, human papillomavirus (HPV) status, and sensitivity to tyrosine kinase inhibitors
por: Bao, Yilin, et al.
Publicado: (2021)

CTLA4 polymorphism and primary Sjögren's syndrome
por: Lester, Susan, et al.
Publicado: (2007)

CTLA-4 based therapy (MDX-010)
por: Korman, A
Publicado: (2003)

CTLA-4 and Autoimmunity: New Twists in the Tale
por: Walker, Lucy S.K.
Publicado: (2015)

Effects of CTLA4-Ig on human monocytes
por: Tono, Toshihiro, et al.
Publicado: (2017)

CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
por: Sobhani, Navid, et al.
Publicado: (2021)

The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
por: Voskens, Caroline J., et al.
Publicado: (2013)

(64)Cu-DOTA-Anti-CTLA-4 mAb Enabled PET Visualization of CTLA-4 on the T-Cell Infiltrating Tumor Tissues
por: Higashikawa, Kei, et al.
Publicado: (2014)

Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice
por: Du, Xuexiang, et al.
Publicado: (2018)

TGFβ2 Induces the Soluble Isoform of CTLA-4 – Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma
por: Khanolkar, Rahul C., et al.
Publicado: (2022)

CTLA-4 CT-60 A/G and CTLA-4 1822 C/T Gene Polymorphisms in Indonesians with Type 1 Diabetes Mellitus
por: Rochmah, Nur, et al.
Publicado: (2022)

Blood PD-1(+)TFh and CTLA-4(+)CD4(+) T cells predict remission after CTLA-4Ig treatment in early rheumatoid arthritis
por: Aldridge, Jonathan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7fcnfc8slccvq92dc2fn2d36mv